Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Cancer and Blood Pressure Management, CARISMA Study
NCT04467021 · View on ClinicalTrials.gov ↗
Study Summary
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Blood Pressure Measurement
- OTHER Clinical Management
Study Locations (20)
Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington
- Aurora Saint Luke's South Shore — Cudahy
- Aurora Health Care Germantown Health Center — Germantown
- Aurora Cancer Care-Grafton — Grafton
- Aurora BayCare Medical Center — Green Bay
- Aurora Cancer Care-Kenosha South — Kenosha
- Aurora Bay Area Medical Group-Marinette — Marinette
- Aurora Cancer Care-Milwaukee — Milwaukee
- Aurora Saint Luke's Medical Center — Milwaukee
- Aurora Sinai Medical Center — Milwaukee
- Vince Lombardi Cancer Clinic - Oshkosh — Oshkosh
- Aurora Cancer Care-Racine — Racine
New York
- Montefiore Medical Center-Einstein Campus — The Bronx
- Montefiore Medical Center-Weiler Hospital — The Bronx
- Montefiore Medical Center - Moses Campus — The Bronx
Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur
- Washington University School of Medicine — St Louis
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center — Philadelphia
- University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh
Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04467021
The ClinicalTrials.gov registry entry for NCT04467021 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 52 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 9 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 5 interventions — of which Quality-of-Life Assessment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04467021 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Wisconsin, New York, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04467021 about?
NCT04467021 is a clinical study titled "Cancer and Blood Pressure Management, CARISMA Study". This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This stud...
What is the current status of trial NCT04467021?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 61 participants. The study started on 2020-10-29. Estimated completion is 2026-08-31.
What conditions does trial NCT04467021 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Cardiovascular Disorder, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04467021?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Best Practice (OTHER), Blood Pressure Measurement (OTHER), Clinical Management (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04467021?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 52 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04467021 being conducted?
This trial has 20 study locations across Missouri, New York, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.